MEDX HOLDINGS, INC.

A WYOMING CORPORATION

COMPANY INFORMATION AND DISCLOSURE STATEMENT

Pursuant to Pink Sheet Basic Disclosure Guidelines

All information in this information and Disclosure Statement has been compiled to fulfill the disclosure requirements of the OTC Markets regarding Pink Sheet Basic Disclosure Guidelines.

No Dealer, salesman or any other person has been authorized to give any information, or to make any representations, not contained herein in connection with the issuer. Such information or representations if made should not be relied upon as having been authorized by the by the issuer and;

Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written.

The undersigned hereby certifies that the information herein is true and correct to the best of their knowledge and belief.

Date: May 2, 2016

MedX Holdings, Inc.

/s/ Kathleen Roberton

Name: Kathleen Roberton
Position: Director and CEO
Kathy@medxholdings.com
Phone: 877-337-3756

MEDX HOLDINGS, INC.
DISCLOSURE STATEMENT

March 31, 2016

Item 1: The exact name of the issuer and the address of its executive offices:

The exact name of the issuer is: MedX Holdings, Inc.
August 12, 2015 – Cantor Group, Inc.
November 13, 2006 – Disaboom, Inc.
September 5, 2006 – Disaboo, Inc.

Item 2: The Address of its principal executive offices:

1621 Central Avenue
Cheyenne, WY 82001

Phone: 877-225-0234
Fax: 954-337-3756
Website: www.medxholdings.com

Item 3: Security Information

Security Symbol:	MEDH
CUSIP Number:	58403T 107
Common Stock:	25,369,016
Par Value:	$0.001 on both Common and Blank Check Preferred

Authorized Share Structure: As of 3/31/2016

Common Stock:	100,000,000
Blank Check Preferred:	100,000,000

Transfer Agent:

Daniel Bell, Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, Colorado 80209
Phone: 303-282-4800

CST currently meets all requirements and is registered under the Securities Exchange Act.

Restrictions on transfer of Securities or suspensions by the SEC in the past 3 months:

None

Item 4: Issuance History

No significant issuances or changes have taken place in the past 12 months.

Item 5: Financial Statements

- Balance Statement
- Profit and Loss Statement
- Statement of Cash Flows
- Financial Notes

MEDX HOLDINGS, INC.
(A Development Stage Company)
Balance Sheet
As of March 31, 2015

	Total	
	As of Mar 31, 2016	As of Dec 31, 2015
ASSETS		
Current Assets		
Bank Accounts		
Checking	5,275.89	1,709.25
Total Bank Accounts	$ 5,275.89	$ 1,709.25
Total Current Assets	$ 5,275.89	$ 1,709.25
Other Assets		
CAPITAL ASSETS	146,000.00	146,000.00
Capitalized Re-Organization Costs	13,000.00	13,000.00
Intellectual Property	200.00	
Total Other Assets	$ 159,200.00	$ 159,000.00
TOTAL ASSETS	$ 164,475.89	$ 160,709.25
LIABILITIES AND EQUITY		
Liabilities		
Current Liabilities		
Other Current Liabilities		
Accrued Liabilities	0.00	0.00
Due to related party	26,927.75	27,000.00
Total Other Current Liabilities	$ 26,927.75	$ 27,000.00
Total Current Liabilities	$ 26,927.75	$ 27,000.00
Long Term Liabilities		
Convertible Notes	$ 11,000.00	
Total Long Term Liabilities	$ 11,000.00	
Total Liabilities	$ 37,927.75	$ 27,000.00
Equity		
Common Stock	4,221.00	4,221.00
Paid-In Capital or Surplus	717,239.00	717,239.00
Retained Earnings	-587,750.75	-587,460.00
Net Income	-7,161.11	-290.75
Total Equity	$ 126,548.14	$ 133,709.25
TOTAL LIABILITIES AND EQUITY	$ 164,475.89	$ 160,709.25

The accompanying notes are an integral part of these fianancial statements.

MEDX HOLDINGS, INC

(A Development Stage Company)

Statement of Cash Flows

January - March 2016 and January - December 2015

	Jan-Mar 2016	Jan-Dec 2015	Cumulative results from September 6 2006 (inception date) to MARCH 31, 2016
OPERATING ACTIVITIES			
Net Loss	$ (7,161)	$ (291)	$ (594,912)
Adjustments to reconcile Net Income to Net Cash provided by operations:			
Accrued Liabilities		(16,000)	-16000
Due to related party	(72)	27,000	26,928
Net cash provided by operating activities	**(7,233)**	**10,709**	**10,928**
INVESTING ACTIVITIES			
Acquire Intelectual Property (LOGO)	(200)		(200)
Capitalized Re-Organization Costs		(13,000)	(13,000)
Purchase of Capital Asset			(146,000)
Net cash provided by investing activities	**(200)**	**(13,000)**	**(159,200)**
FINANCING ACTIVITIES			
Increase in Long Term liability (Convertible Notes)	11,000		11,000
Common Stock		-	4,221
Paid-In Capital			717,239
Retained Earnings		4,000	4,000
Net cash provided by financing activities	**11,000**	**4,000**	**725,460**
Net cash increase for period	3,567	1,709	5,276
Cash at beginning of period	1,709		-
Cash at end of period	**$ 5,276**	**$ 1,709**	**$ 5,276**

The accompanying notes are an integral part of these financial statements.

MEDX HOLDINGS, INC.

(A Developing Stage Company)

Profit and Loss

January - March 2016 & January - December 2015

	Jan -Mar 2016	Jan - Dec 2015	Cumulative results from September 6, 2006 (Inception date) to March 31, 2016
Income			
Total Income			
Expenses			
Professional Fees	$ 1,924.00	$	$ 26,424
Office/General Administrative Expenses	43.00	290.75	5241
FINRA Compliance	4,425.00		4425
Travel	769.11		769
Total Expenses	$ 7,161.11	$ 290.75	$ 594,912
Net Loss	-$ 7,161.11	-$ 290.75	$ (594,912)

STATEMENT OF STOCKHOLDERS' DEFICIT

BASIC LOSS PER COMMON SHARE	0.00	0.00
FULLY DILUTED LOSS PER COMMON SHARE	0.00	0.00
Weighted Average number of Common Shares Outstanding	25,569,016	25,369,016
Fully diluted weighted average number of Shares Outstanding		65,369,016

The accompanying notes are an integral part of these financial statements.

MEDX HOLDINGS, INC.

(A Development Stage Company)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

March 31, 2016

NOTE 1 - SUMMARY OF OPERATIONS AND BASIS OF PRESENTATION

Medx Holdings, Inc. formerly Cantor Group Inc. (the "Company") was incorporated in the State of Colorado on December 23, 2015. The company has an established fiscal year end of December 31.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Cash and Cash Equivalents

The company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Financial Instruments

The carrying value of the company's financial instruments approximates their fair value because of the short maturity of these instruments.

Basic and Diluted Net Loss per Share

The Company computes loss per share in accordance with "ASC-200". "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Dilutive loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has issued four notes (DUE RELATED PARTIES) which are potential dilutive instruments and accordingly, basic loss and diluted loss per share are presented. The Basic Common Stock authorized is 100,000,000 shares. As of

03/31/2016 the number of issued shares is 25,569,016 outstanding. The weighted average of fully diluted shares is 65,569,016.

NOTE 3 – GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has restructured its board and its management team and has raised equity capital to position the company as a holding company focused on acquisition and development of businesses primarily in the medical products industry. The Company is utilizing a new form of collaborative governance to create added value.

The ability of the Company to continue as a going concern is dependent upon its continued ability to successfully accomplish the plans descried in the preceding paragraph. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 4 - RELATED PARTY TRANSACTION

As of March 31, 2016 the Company owed $ 12,000.00 in a Convertible Note with four (4) individuals each owning ¼ each of the note via a partial Note Assignment. The notes remain non-interest bearing. The notes convert at $0.0001 up to 48,000,000 common Shares.

On November 17, 2015, Small Cap Pro LLC, funded a special purpose account on behalf of MEDX HOLDINGS, INC. in the amount of $ 15,000.00 with the sole purpose of providing working capital to re-structure the operations, move the state of domicile from Colorado to Wyoming, and to establish corporate operations in order to implement the current strategic business plan. This note carries a statutory interest rate, is unsecured and is due on demand. As of 12/31/2015 the un-used amount in the SPE account was $ 1709.25. The board of directors authorized that the claim of $ 1709.25 towards Medx Holdings Inc. be released and the account be returned to its beneficial owner, Small Cap Pro LLC. Small Cap Pro LLC is wholly owned by the principle shareholder of MedX Holdings, Inc.

NOTE 5 – CAPITAL STOCK

As of March 31, 2016 the Company has:

Authorized Common Shares	100,000,000 Par Value $0.001
Authorized Blank Check Preferred	100,000,000 Par Value $0.001
Issued and outstanding:	25,569,016

NOTE 6 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined that there are no significant events that need to be disclosed.

Item 6: Nature of the Issuers Business

MEDH was sold to Kathleen Roberton on January 14, 2016 by Donald Schellpfeffer, MD/PHD. Ms. Roberton was appointed as President and Chief Executive Officer.

MedX has made substantial strides regarding our newly developed business model. MedX has trademarked MEDX and now has a fully developed website.

MedX Holdings is focused on the acquisition of profitable businesses in the medical sector. We use a very unique business model known as Collaborative Profit which is proven to be a superior governance model. We are currently working with two different profitable business and plan to sign a Letter of Intent by the end of Q2. In addition to our focus on acquisitions, MedX has also chosen to enter into the Nutraceutical and Pharmaceutical sales business. We are in the process of securing the rights to a Pharmaceutical product that is known to have vast market appeal currently. In addition, we are defining certain products that the company will "White Label" in the Nutraceutical arena and in final stages of negotiations to secure the rights to certain Pharmaceutical formulations. This fits well with our main focus of acquiring profitable business in the medical sector.

The Company is not currently subject to any legal action or in default of any debt covenants.

A. The form of organization of the Issuer:

MedX Holdings, Inc. is a Wyoming Corporation

B. The year that the issuer (or predecessor was organized):

The Company was incorporated on September 5, 2006 as Disaboo, Inc. under the laws of the State of Colorado.

Item 7 Describe the Issuer's Facilities

Office Location:

1621 Central Avenue
Cheyenne, WY 82001

The Company is actively seeking permanent office space in Jackson Hole, Wyoming.

Item 8: Officers, Directors and Control Persons:

A. On January 14, 2016 Donald Schellpfeffer, MD/PHD stepped down as CEO and President of the Company and Kathleen Roberton was appointed CEO and President. Donald Schellpfeffer was removed for the Board and returned his shares to treasury. Kathleen Roberton is the only Board Member.

B. Legal/Disciplinary History

None

C. Beneficial Owner

Kathleen Roberton
1621 Central Avenue
Cheyenne, WY 82001

Percentage: Greater than 99%

Item 9: Third Party Providers

Legal Counsel:

Lorin A. Rosen, Esq.
Managing Attorney
Lar Law Firm
6 Butler Court
Centereach NY 11720

Accountant:

Irick CPA
Box 732
Counselor, NM 87018

Subsequent Events:

None

Item 10: Issuer Certification

I Kathleen Roberton certify that:

1. I have reviewed this Quarterly report; and
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to made the statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results operations and cash flows of the issuer as of, and for, the period presented in this disclosure.

/s/ Kathleen Roberton, CEO

Kathleen Roberton, CEO